✦ LIBER ✦

W1093 Predictors and Timing of Adalimumab (ADA) Dose Escalation in Patients with Crohn's Disease (CD)

✍ Scribed by Cohen, Russell D.; Lewis, Jeffrey R.; Turner, Hannah; Hanauer, Stephen B.; Rubin, David T.

Book ID: 123236948
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 99 KB
Volume: 136
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(09)63007-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Predictors of adalimumab dose escalation

Predictors of adalimumab dose escalation in patients with crohn's disease at a tertiary referral center

✍ Russell D. Cohen; Jeffrey R. Lewis; Hannah Turner; Laura E. Harrell; Stephen B. 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 167 KB 👁 2 views

Background: Pivotal trials for adalimumab (ADA) demonstrated effectiveness versus placebo for induction and maintenance of remission in moderate to severely active Crohn's disease (CD). Although the approved maintenance regimen in the U.S. is 40 mg subcutaneously every 14 days, some patients require

Sa1918 Better off Naïve: Predictors of A

Sa1918 Better off Naïve: Predictors of Adalimumab Dose Escalation in Patients With Crohn's Disease

✍ Moncrief, Karli; Steinhart, A. Hillary; Croitoru, Ken; Newman, Alvin; Nguyen, Ge 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 122 KB

Predictors of dose escalation of adalimu

Predictors of dose escalation of adalimumab in a prospective cohort of Crohn’s disease patients

✍ E. Bultman; C. de Haar; A. van Liere-Baron; H. Verhoog; R. L. West; E. J. Kuiper 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 197 KB

Adalimumab dose escalation and dose de-e

Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients

✍ Baert, Filip; Glorieus, Elien; Reenaers, Cathérine; D'Haens, Geert; Peeters, Har 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 446 KB

W1106 Increased BMI Is Not Associated wi

W1106 Increased BMI Is Not Associated with Dose Escalation or Failure of Adalimumab Therapy in Crohn's Disease

✍ Qumseya, Bashar; Naik, Amar S.; Ananthakrishnan, Ashwin N.; Zadvornova, Yelena; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

P486 Factors influencing the time to and

P486 Factors influencing the time to and outcome of dose escalation of adalimumab in Crohn's disease patients who achieved steroid-free remission on adalimumab

✍ Mantzaris, G.J.; Kyriakos, N.; Papamichael, K.; Archavlis, E.; Tzannetakou, X.; 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 69 KB